+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rituximab"

Mexico Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Mexico Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027

  • Report
  • September 2022
  • 74 Pages
  • Mexico
From
From
From
Rituximab Biosimilars Market Report and Forecast 2023-2031 - Product Thumbnail Image

Rituximab Biosimilars Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
From
Disease Analysis: Osteoporosis - Product Thumbnail Image

Disease Analysis: Osteoporosis

  • Report
  • March 2021
  • 48 Pages
  • Global
From
From
Loading Indicator

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs. Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis. The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more